Aytu BioScience (AYTU) shares are trading at lower $1.19 and the average recommendation for the stock is Strong Buy.
To add more color to this target, the company’s high over the last year is $2.99 and the low is $0.34. Over the last 52 weeks, AYTU is down -11.11% while the S&P 500 is up 20.39%%. The catalyst for this interesting swing is the company’s anticipated earnings report.
Aytu BioScience (AYTU) upcoming earnings analysis
Aytu BioScience is estimated to report earnings on 09/24/2020. According to analysts, the consensus EPS forecast for the quarter is $-0.05. The reported EPS for the same quarter last year was $-1.3. The analyst algorithm expects the price of Aytu Bioscience to increase slowly for the rest of the year with a price target of $3.
Aytu BioScience (AYTU) company outlook
AYTU has seen increased volume after this news and investors are putting their support behind the value proposition. Traders will also note the company’s earnings per share came in at -1.54 for previous earnings quarter. Aytu BioScience also noted assets of $158.95 million at the end of the last quarter. Investors should also keep an eye on sector updates as AYTU has historically followed its peers on positive news.
All told, Aytu BioScience Inc. AYTU has strung together solid data and demonstrated underlying fundamentals. At its current valuation, AYTU represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.
Aytu BioScience is now commanding a market cap of 136.5M (previously 145.40M) and a float of 110.2M (previously 116.08M). AYTU is increasing its credibility in this sector and that could lead to more upside down the line.
Aytu BioScience (AYTU) company updates
A couple weeks ago we wrote that Aytu BioScience has confirmed delivery of Healight devices. I predict that trials are getting ready to start or has started already. As for Natesto, it is showing promising results.
Ranjith Ramasamy, an Associate Professor in the Department of Urology, University of Miami, focuses on clinical work in treating male infertility and sexual dysfunction, he is involved in several research projects. One such project investigated a novel treatment for low testosterone, a nasal gel known as Natesto. An initial clinical trial showed that Natesto is a promising treatment option for men who want to preserve reproductive abilities while improving low testosterone levels.
Furthermore, testosterone replacement therapy is becoming increasingly available due to growing awareness of available products and direct consumer marketing. The aim of testosterone treatment is to achieve testosterone levels within the normal range, whilst having the maximum effects in symptom alleviation.
Is Aytu BioScience (AYTU) and good investment?
Shares of Aytu BioScience (AYTU) appear to be a very good investment option, the Money Midnight Indicator is expecting its price to increase considerably in the next several months. The majority of the metrics point to this investment being highly attractive.
